KapaVax (VXD005)
Infections caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae
ResearchActive
Key Facts
Indication
Infections caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae
Phase
Research
Status
Active
Company
About VAXDYN
VAXDYN is a private, pre-revenue biotech focused on developing novel vaccines against multi-drug resistant bacterial pathogens, a critical threat in the post-antibiotic era. Its core technology platform transforms an inactivated, LPS-null (endotoxin-free) whole-cell vaccine candidate into multivalent vaccines targeting 'superbugs' like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. The company is supported by non-dilutive funding (e.g., CARB-X, EU grants) and is advancing its lead candidate, AcinetoVax, towards clinical development while expanding its pipeline.
View full company profile